Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
27 September 2018Website:
http://www.arvinas.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:47:46 GMTDividend
Analysts recommendations
Institutional Ownership
ARVN Latest News
NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:
– On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be presented at San Antonio Breast Cancer Symposium in December 2024 – – Recently presented new preclinical data for the PROTAC LRRK2 degrader ARV-102 demonstrating that LRRK2 degradation affects biomarkers in the CSF – - $1.1 billion in cash, cash equivalents and marketable securities as of Sept. 30, 2024 - – Company to host conference call today at 8:00 a.m.
NEW HAVEN, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that employees from 16 states participated in the Company's third annual “Arvinas Impact Day,” a company-wide day of service where employees joined forces to give back to their communities, engaging in various volunteer activities that made a tangible difference across the Greater New Haven area and beyond.
NEW HAVEN, Conn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review third quarter 2024 financial results and provide a corporate update during a live webcast on Wednesday, October 30, 2024, at 8:00 a.m. ET.
NEW HAVEN, Conn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.25 per share a year ago.
Arvinas (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn.
– Preclinical data for ARV-393 presented at t he European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma –
NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced Ian Taylor, Ph.D. has been promoted to President of Research and Development and Angela Cacace, Ph.D. has also been promoted and will succeed Dr. Taylor as Chief Scientific Officer of the company. Dr. Taylor and Dr. Cacace will assume these new roles effective immediately and report to John Houston, Ph.D., Chairperson, President and Chief Executive Officer.
What type of business is Arvinas?
Arvinas, Inc. is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases by discovering, developing, and commercializing treatment methods that target disease-causing proteins. Arvinas utilizes its patented PROTAC Discovery Engine platform. The company was founded in 2015 and is based in New Haven, Connecticut. The therapeutic focus of the issuer includes oncological diseases, neurological disorders, and other serious illnesses. Arvinas, Inc. has two leading product candidates: ARV-110 - for the treatment of men with metastatic castration-resistant prostate cancer ARV-471 - for the treatment of patients with locally advanced or metastatic ER-positive / HER2-negative breast cancer.
What sector is Arvinas in?
Arvinas is in the Healthcare sector
What industry is Arvinas in?
Arvinas is in the Biotechnology industry
What country is Arvinas from?
Arvinas is headquartered in United States
When did Arvinas go public?
Arvinas initial public offering (IPO) was on 27 September 2018
What is Arvinas website?
https://www.arvinas.com
Is Arvinas in the S&P 500?
No, Arvinas is not included in the S&P 500 index
Is Arvinas in the NASDAQ 100?
No, Arvinas is not included in the NASDAQ 100 index
Is Arvinas in the Dow Jones?
No, Arvinas is not included in the Dow Jones index
When was Arvinas the previous earnings report?
No data
When does Arvinas earnings report?
Next earnings report date is not announced yet